A campaign backed by Kyowa Kirin, Amgen and Sanofi is calling on prominent organizations with medical websites to bring their ...

Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease AreasKHK4083 Depletes OX40-Expre ...

Amgen has agreed to co-develop and co-commercialize with Kyowa Kirin its Phase III-bound KHK4083, a potentially first-in-class treatment for atopic dermatitis, through a collaboration that could ...

THOUSAND OAKS, Calif. and TOKYO, June 1, 2021/ PRNewswire/-- Amgen and Kyowa Kirin Co., Ltd. today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's ...

Amgen and Kyowa Kirin Collaboration On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, ...

Amgen Inc. AMGN announced that it has entered into an agreement with Japanese pharmaceutical company Kyowa Kirin Co to jointly develop and commercialize KHK4083 for the treatment of atopic ...

Amgen is paying Kyowa Kirin $400 million to share in the development of a drug that could offer a new approach to treating atopic dermatitis, a form of eczema.

Kyowa Kirin will retain exclusive rights in Japan, and co-promote with Amgen outside the US. The further potential upside comes from its use in applications for other autoimmune diseases which is ...

THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...